KRRO Unusual Options Activity — 2026-04-06

🐻 KRRO $2M Deep ITM Put — Someone Is Betting Korro Bio's Recovery Rally Is Toast

📅 April 6, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Signal

At 14:03:27 today, someone dropped $2 million buying 3,610 deep in-the-money put contracts on Korro Bio (KRRO) — the $20 strike with only 11 days to expiration. With the stock trading at $14.64, these puts are $5.36 in-the-money (37% ITM), and the prior open interest was a mere 1 contract. This is not a hedge. This is not a roll. This is a $2 million conviction bet on one of two things: either the stock continues falling hard through April 17, or a large holder is locking in gains from a position built near the post-crash lows. Either way, this is the biggest options trade on KRRO in recent memory — and it deserves a closer look.

---

📊 Company Overview

Korro Bio (KRRO) is a Cambridge, Massachusetts-based clinical-stage biotech focused on RNA editing therapeutics for rare genetic diseases:

• 🧬 What they do: Develops genetic medicines using proprietary RNA editing technology (ADAR-mediated) to correct disease-causing mutations at the RNA level — without permanently altering DNA
• 💰 Market Cap: ~$208M (micro-cap biotech)
• 📉 52-Week Range: $5.20 — $55.89
• 📈 Exchange: NASDAQ
• 👥 Shares Outstanding: ~14.4M
• 🔬 Lead Program: KRRO-121 for hyperammonemia in urea cycle disorders (UCD) and hepatic encephalopathy — nominated as development candidate in Q1 2026
• 💸 Cash Runway: Raised $85M in oversubscribed private placement (March 2026); FY 2025 burn rate approximately $79M in free cash flow usage
• 🤝 Key History: Former Novo Nordisk collaboration on KRRO-110 (halted after trial failure); rebuilt pipeline around KRRO-121

---

💰 The Option Flow Breakdown

📊 The Tape

🤓 What This Actually Means

Let's break this down precisely:

• 💸 $2 million deployed: 3,610 contracts at $5.45 each ($5.45 x 100 shares x 3,610 = ~$1.97M)
• 📉 Strike $20 is $5.36 in-the-money — the stock at $14.64 is already 37% below the strike; these puts have massive intrinsic value right now
• ⏰ Only 11 days to expiration (April 17, 2026) — there is almost no time value left in this trade; this is essentially a bet on delta, not theta
• 📊 Volume/OI ratio = 3,610x — prior OI was a single contract. Every single contract in this position is brand new. Vol/OI of 3,610 is astronomical, confirming this is a Buy-to-Open (BTO) — entirely fresh exposure
• 🤝 MID fill — executed at the midpoint, a hallmark of an institutional, negotiated block trade
• 🎯 Breakeven at expiration: $14.55 ($20 strike — $5.45 premium paid) — the stock only needs to stay below $14.55 to be profitable. At current spot of $14.64, the trader is already nearly in profit
• 💡 Intrinsic value: $5.36 vs. $5.45 paid — the trader paid only $0.09 in time premium (just 1.7% extrinsic). This is an extremely efficient way to get short delta in a hurry

What is this trade actually doing?

At $5.36 ITM with 11 days left, these puts have a delta of approximately -0.90 to -0.95. That means the trader effectively has short exposure to ~342,000 shares of KRRO (3,610 contracts x 100 shares x 0.95 delta). At $14.64 per share, that's synthetic short exposure worth **$5 million in notional value** — achieved for $2M in premium.

Two plausible interpretations:

1. 🐻 Pure bearish bet: The trader believes KRRO falls further through April 17. Given the stock just surged +79% YTD and broke above $14 today, this could be a bet that the rally is exhausted and the stock retraces back toward $11-12 before OPEX.

2. 💰 Profit lock-in / synthetic short hedge: A large shareholder who accumulated near the December lows ($5.20) and now holds stock near $14.64 could buy deep ITM puts to lock in their gains without triggering a taxable sale. The delta on these puts effectively hedges ~95% of the downside below $14.55, functionally "selling" the position without creating a tax event.

The near-zero extrinsic value ($0.09 time premium) makes interpretation #2 particularly compelling — if this were a pure speculative bet, you could buy OTM puts much cheaper. Paying $5.45 for a deep ITM put is the behavior of someone protecting a large long position, not someone making a high-risk directional gamble.

---

📈 Technical Setup / Chart Check-Up

YTD Performance

KRRO is up +79.1% YTD in 2026, starting the year at $8.05 and trading at $14.42 as of market close today. The chart tells a recovery story with important caveats:

• 💥 January recovery launch: Stock started 2026 at $8.05, already recovering from the November 2025 crash lows near $5.20; Analyst Day on January 27 provided a meaningful catalyst as the company presented KRRO-121 data
• 🚀 February spike: Surged to the $13-14 range in early February on analyst upgrades and growing confidence in the KRRO-121 program
• 📊 March consolidation: Traded sideways in the $10.50-$13.50 range through most of March despite the $85M private placement announcement on March 9
• 📈 April breakout: A sharp move higher today (April 6) put the stock at $14.64, breaking above the March trading range with volume confirmation (~630K shares vs. average)
• 📉 Max drawdown: -22.88% intra-year — the stock has had sharp reversals even within this recovery trend
• 📊 Annualized volatility: 85.1% — this stock moves violently. An 85%+ implied vol environment means options pricing reflects genuine uncertainty

Key takeaway: KRRO has staged a powerful recovery from its post-trial-failure lows, but it remains deeply scarred. The stock is still down 74% from its 52-week high of $55.89. The +79% YTD gain is impressive but off a devastated base. The question this put trade raises: is today's breakout above $14 a false dawn, or the beginning of a sustained re-rating?

Gamma-Based Support & Resistance Analysis

Current Price: $14.42-$14.64

The gamma exposure map for KRRO reveals a very thin, illiquid options market — which makes this $2M put trade even more anomalous:

🔵 Support Levels (Put Gamma Below Price):

• $12.50 — The only meaningful support level in the data, with 0.149M total gamma exposure, sitting 13.5% below current price. This is a thin but real floor where put sellers (dealers) would step in to support the price
• There is virtually no gamma support between $12.50 and current price — meaning a drop from $14.64 toward $12.50 could happen fast with minimal dealer resistance

🟠 Resistance Levels (Call Gamma Above Price):

• $15.00 — The nearest resistance level, just 3.8% above current price, with 0.003M call gamma. Extremely thin — this resistance can be blown through easily
• The overall gamma landscape is nearly empty above $15, suggesting the options market has very little positioning to create a "gravitational pull" either way beyond $12.50 and $15

Net GEX Bias: Bullish (total call gamma 0.161M vs. total put gamma 0.072M) — dealers are net long gamma from calls, which typically creates a pinning/dampening effect. But with such thin overall gamma, the market maker influence is minimal. Price can move freely in both directions.

What this means for the put trade: The $20 strike on this put is far above all current gamma levels. The put's value is almost entirely intrinsic ($5.36 of $5.45). Gamma effects at the $20 strike are irrelevant — what matters is where the stock goes over the next 11 days, and the gamma map shows very little structural support between $12.50 and $14.64.

Implied Move Analysis

Options market pricing for April 17 OPEX (11 days out):

• 📅 April 17 OPEX (THIS TRADE): ±$2.74 (±19.01%) from current $14.42 spot
  • Upper range: $17.16
  • Lower range: $11.68

Translation: The options market is pricing in a potential move to $11.68 on the downside and $17.16 on the upside over the next 11 days. That is a massive 19% implied move for less than two weeks — reflecting this stock's known explosive volatility.

Key insight for this put trade:

• The $14.55 breakeven is well within the implied move range (sits between current price $14.42 and lower range $11.68)
• The put becomes deeply profitable below $11.68 — which the market itself assigns non-trivial probability
• The put loses money only if KRRO surges above $14.55 — still within the upper implied range of $17.16
• This means the options market itself is telling us: this trade breaks even if the stock moves as little as -0.1 from here, and could be very profitable if the stock returns to its pre-April breakout range

---

🎪 Catalysts

🔥 Upcoming Catalysts

Q1 2026 Earnings - Expected Late April/Early May 2026 📊

This is the most likely near-term trigger. After the March 12 full-year 2025 results release, Q1 2026 results should arrive in late April or early May. Key items:

• 💰 Cash position update post-$85M private placement (raised March 9)
• 🔬 KRRO-121 IND filing timeline — the company nominated this as a development candidate; when does the IND go in?
• 📋 Any update on the KRRO-110 program wind-down or asset monetization
• 💸 Updated burn rate and cash runway guidance

KRRO-121 IND Filing / Clinical Initiation Timeline 🧬

KRRO-121 targets hyperammonemia in urea cycle disorders (UCD) and hepatic encephalopathy. This is now the company's lead program after KRRO-110 failed. The development candidate nomination was announced March 12, 2026. Key milestones:

• 📋 IND filing (Investigational New Drug application) likely in mid-to-late 2026
• 🏥 First-in-human dosing could come in late 2026 or early 2027
• 📊 Any preclinical data or biomarker update would be a major catalyst

Medical Conferences - Spring 2026 🎤

• TD Cowen Health Care Conference presentation occurred February 25
• AASLD (liver disease), ASHP, or rare disease conferences may feature KRRO-121 data
• Any conference presentation with KRRO-121 preclinical data could move the stock

Potential Partnership / Licensing Discussions 🤝

• Following Novo Nordisk collaboration termination (post KRRO-110 failure), the company has a clean slate
• The $85M financing brings in Venrock Healthcare as a new lead investor — a signal that serious biotech-focused capital sees value in the RNA editing platform
• A new large pharma partnership could be announced at any time and would be transformative for this sub-$250M company

✅ Recent Catalysts (Already Happened)

November 13, 2025 — KRRO-110 Clinical Failure (-79% in one day) 💥

This is the defining event for the entire current trade setup. KRRO-110, the company's then-lead RNA editing candidate (developed in partnership with Novo Nordisk for hepatic ADAR editing), produced clinical trial results that "fell short." The stock collapsed from $31.42 to $6.50 in a single session — a 79.3% single-day wipeout. This is the scar tissue that defines everything about KRRO today: the low base, the analyst skepticism, the massive implied volatility, and the deep ITM puts at $20 that represent the entire pre-crash zone.

Post-KRRO-110 Restructuring — Q4 2025

The company halted its collaboration with Novo Nordisk and conducted layoffs to extend runway. This pivot was painful but necessary — it refocused the company around KRRO-121 and the GalNAc-conjugated RNA editing platform.

January 27, 2026 — Virtual Analyst Day

Korro hosted an Analyst Day presenting KRRO-121 for hyperammonemia in UCD/hepatic encephalopathy. Included clinical hepatologist perspectives on ammonia-driven disease burden and the medical need. This presentation triggered analyst upgrades and the late-January stock rally.

March 9, 2026 — Oversubscribed $85M Private Placement

Led by new investor Venrock Healthcare Capital Partners with participation from new and existing investors. This was oversubscribed — meaning institutional demand exceeded the offering size. Proceeds fund advancement of KRRO-121 and other RNA editing programs. This was a major show of confidence from sophisticated biotech investors and directly funded the company's survival through multiple anticipated milestones.

March 12, 2026 — Q4 2025 Financial Results + Development Candidate Nomination

Formal announcement that KRRO-121 has been nominated as a development candidate for hyperammonemia. The company rebranded its pipeline strategy around GalNAc-conjugated RNA editing and confirmed advancement of multiple programs.

Piper Sandler Upgrade (January 2026) + Raymond James Upgrade (March 2026)

• Piper Sandler raised target from $11 to $30 in late January 2026
• Raymond James upgraded from Hold to Buy with a $23 target in mid-March 2026
• Both reflect recovering analyst confidence in KRRO-121's potential — though the consensus price target of $34.80 is still 2.4x current price, reflecting high uncertainty

---

🎲 Price Targets & Probabilities

Using the implied move data, gamma map, analyst targets, and options structure, here are the scenarios through the April 17 OPEX:

📈 Bull Case — Stock Rallies (20% probability)

Target: $17-$18 range by April 17

How we get there:

• 🚀 Continued momentum from today's $14.64 breakout, driven by biotech sector rotation into small-cap RNA plays
• 📊 Early Q1 earnings guidance or pipeline update beats expectations
• 🤝 Partnership rumor or news flow around KRRO-121 licensing
• 📈 General biotech sector tailwinds (positive FDA decisions elsewhere, sentiment shift)
• 💰 Short squeeze — with ~14.4M shares outstanding and 79% YTD run, any rush to cover short positions could push to the $17.16 implied upper range

Put trade P&L at $17: Puts worth $3.00, loss = -$2.45/contract x 3,610 = -$884K loss (44% of premium) Put trade P&L at $18: Puts worth $2.00, loss = -$3.45/contract x 3,610 = -$1.25M loss (63% of premium)

This is the scenario where the put buyer regrets the timing — or where their hedge works as intended (the underlying long position rallied, they gave back some premium on the hedge).

🎯 Base Case — Stock Consolidates or Mild Decline (50% probability)

Target: $12-$15 range through April 17

Most likely scenario:

• ✅ After today's sharp $14.64 breakout on elevated volume, the stock digests gains and consolidates
• 📊 No immediate catalysts to push above the $15.00 gamma resistance
• ⚖️ Market recognizes KRRO remains a pre-clinical-stage RNA editing company with no near-term revenue
• 📉 Profit-taking from investors who accumulated near December lows ($5-8 range) creates selling pressure

Put trade P&L at $14 (flat): Puts worth $6.00, profit = +$0.55/contract x 3,610 = +$198K gain (10% ROI) Put trade P&L at $12: Puts worth $8.00, profit = +$2.55/contract x 3,610 = +$920K gain (46% ROI) Put trade P&L at $11.68 (lower implied range): Puts worth $8.32, profit = +$2.87/contract x 3,610 = +$1.04M gain (52% ROI)

This is where the trade makes money if the stock simply stops going up or retreats modestly. The breakeven is just 9 cents below current price — an extremely low bar.

📉 Bear Case — Stock Collapses (30% probability)

Target: Below $11.68 by April 17

What could go wrong (for the stock):

• 😰 Unexpected negative news flow — failed meeting with FDA, IND setback, or safety signal in preclinical KRRO-121 data
• 💸 Lock-up expiration or private placement share registration creating supply pressure (March $85M PP investors may have registration rights)
• 📉 Broader biotech selloff amid macro risk-off environment; small-cap biotechs disproportionately hit
• ⚠️ The post-KRRO-110 crash psychology is fresh — traders remember this stock went from $31 to $6.50 in a day. Any ambiguous news could trigger panic selling
• 🔬 No real near-term binary catalyst (IND filing is months away) means the stock must float on sentiment alone — sentiment is fragile for post-failure biotechs

Put trade P&L at $10: Puts worth $10.00, profit = +$4.55/contract x 3,610 = +$1.64M gain (82% ROI) Put trade P&L at $8 (near December 2025 lows): Puts worth $12.00, profit = +$6.55/contract x 3,610 = +$2.37M gain (119% ROI) Put trade P&L at $5.20 (52-week low): Puts worth $14.80, profit = +$9.35/contract x 3,610 = +$3.37M gain (169% ROI)

The deep ITM structure means every dollar the stock falls below $14.55 is a near-dollar gain for this position. Maximum profit is theoretically capped at $20/share (if KRRO goes to zero), for a maximum gain of $14.55/contract x 3,610 = $5.25M (263% ROI).

---

📐 Greeks Analysis

For the KRRO20260417P20 at $5.45 with spot $14.64 and 11 DTE:

Key Greek insight: These puts are delta-dominant. With only $0.09 in time value, the entire position is essentially a leveraged short stock position. The trader is not playing volatility (Vega is tiny), not playing time decay (Theta is minimal relative to intrinsic), and not playing a gamma scalp. This is pure directional delta.

---

💡 Trading Ideas

🛡️ Conservative: "Follow the Smart Money Down" — Bear Put Spread

Play: Buy the KRRO April 17 $15 put, sell the KRRO April 17 $12 put

Structure: $15/$12 bear put spread, 11 days to expiration

Why this works:

• 📊 Captures bearish thesis with defined, limited-cost risk vs. buying ITM puts outright
• 💰 Net debit approximately $1.00-$1.50 per spread — dramatically cheaper than the deep ITM approach
• 🎯 Max profit of $1.50-$2.00 if KRRO below $12 at April 17 OPEX (2:1 risk/reward)
• 📉 The $12.50 gamma support level from our GEX data suggests $12 is a meaningful floor — the short put at $12 aligns with this structural support
• ⏰ 11 DTE means you're capturing maximum theta decay on the short $12 put while riding delta on the long $15 put
• 📊 Breakeven around $13.50-$14.00 — a range the stock could easily retest after today's spike

Position sizing: Risk 1-3% of portfolio. 20 spreads at ~$125 net debit = ~$2,500 risk for ~$4,000-$6,000 max profit.

Risk level: Low-Moderate (defined risk) | Skill level: Intermediate

⚖️ Balanced: "Volatility Crush After the Spike" — Short-Dated Calendar Put Spread

Play: Buy May 2026 $13 put, sell April 17 $13 put

Why this works:

• 🎯 Profits if KRRO stays near or falls to $13 by April 17 OPEX, then continues lower into May
• 💸 The April 17 puts will decay rapidly in 11 days (theta plays in your favor on the short leg)
• 📊 The May put preserves longer-term downside exposure if the thesis plays out over weeks
• ⚖️ Net debit likely $0.50-$1.00 per spread — low cost for multi-month directional exposure
• 📈 Works well if volatility remains elevated (benefits from Vega on the long May put)
• 🎢 The calendar benefits from time decay discrepancy: the near-dated short put decays faster than the far-dated long put

Position sizing: 15-30 spreads at ~$75-100 net debit = ~$1,500-$3,000 risk.

Risk level: Moderate (can lose full debit if stock moves sharply in either direction) | Skill level: Advanced

🚀 Aggressive: "Mirror the Whale (Cheaper)" — OTM April 17 Puts

Play: Buy KRRO April 17 $13 or $12 puts outright

Why this works (and the risks):

• 💥 Much cheaper than the $20 strike the institutional trader bought — lower upfront cost, but OTM means you need the stock to actually fall
• 📊 At ~$0.50-$1.50 per contract, these puts give you 10:1 leverage if the stock drops to the implied lower range of $11.68
• ⏰ 11 DTE = maximum theta decay will accelerate every day — you need the stock to move fast
• 🎯 If KRRO falls from $14.64 to $11.68 (the options market's expected lower bound), OTM puts could be worth $1.32, potentially a 2-3x return
• 📉 If KRRO stays flat or rallies, you lose 100% of the premium paid

The math on OTM puts:

• $13 put at ~$0.80: if stock falls to $11.68, worth $1.32 → +65% gain
• $12 put at ~$0.40: if stock falls to $11.68, worth $0.32 → -20% loss (not enough move)
• $13 put at ~$0.80: if stock rises to $16, worth ~$0.00 → -100% loss

Position sizing: Speculative — risk only what you're prepared to lose entirely. 20 contracts at $80 = $1,600 maximum risk.

Risk level: HIGH (100% premium at risk) | Skill level: Intermediate-Advanced

---

⚠️ Risk Factors

For anyone considering a bearish position on KRRO:

• 🚀 Short squeeze potential is real: With only ~14.4M shares outstanding and a 79% YTD run that is gathering momentum, this is a very small float. Any positive catalyst — even a vague partnership rumor — could ignite a sharp short squeeze that overwhelms put positions. Biotech short squeezes can be violent and fast.

• 🔬 No near-term binary catalyst (bullish or bearish): Unlike pre-PDUFA or pre-data-readout situations where bearish puts make clear sense, KRRO's next clear catalyst (IND filing for KRRO-121) is months away. Absent a catalyst, the stock may simply drift — and drifting sideways above $14.55 is a full loss for the put buyer.

• 💰 The $85M private placement is freshly deployed: Korro raised $85M in early March 2026 from sophisticated investors including Venrock Healthcare. These investors bought at lower prices and have long-term conviction in KRRO-121. They are unlikely to be aggressive sellers at current levels.

• 📋 Analyst consensus is strongly bullish: 10 analysts cover KRRO with a consensus Buy rating and a $34.80 average price target — 2.4x current price. Analyst upgrades from Piper Sandler and Raymond James are recent (January and March 2026). Any new upgrade or target raise could gap the stock higher and quickly destroy the put trade value.

• 🧬 RNA editing is a hot scientific area: Following the success of ADAR-based RNA editing in academic and early clinical settings, any positive competitor data (Wave Life Sciences, ProQR, Vico Therapeutics) or validation event can lift the entire sector and carry KRRO with it.

• ⏰ 11-day expiration leaves almost no room for error: If the put buyer is wrong about direction, they have no ability to wait it out. Every day that passes without a decline kills the $0.09 in remaining time value. By day 5, the position is entirely intrinsic. If KRRO rallies even 5% to $15.37, the puts are worth approximately $4.63 — an $0.82/contract loss ($296K on the full position).

• 📉 The November 2025 crash is a double-edged sword: Yes, KRRO can crash fast — the 79% single-day drop proves it. But the stock has also survived that crash, raised $85M, and rebuilt institutional support. The conditions that caused the KRRO-110 collapse (a clinical data readout) are not present in the next 11 days.

---

🎯 The Bottom Line

Here's what we know: A sophisticated institutional player just put $2 million into the deepest, most illiquid puts available on Korro Bio — $20 strike puts expiring in 11 days, with prior OI of just 1 contract. The position is 37% in-the-money, the time value is essentially zero, and the breakeven is just 9 cents below the current stock price. This is not a speculative lottery ticket. This is surgical precision.

The two most likely explanations:

1. 🔒 Profit protection / synthetic short hedge: A large shareholder who accumulated KRRO near the December 2025 lows of $5-8 now holds stock at $14.64 and wants to lock in gains heading into the April 17 OPEX without selling shares (tax efficiency, avoiding ownership disclosure triggers, or maintaining upside participation). The deep ITM puts are the cheapest, most efficient way to accomplish this in a thin market.

2. 🐻 Directional bearish bet: Someone believes KRRO's 79% YTD rally is overdone for a company that is still pre-IND, has no revenue to speak of, and just raised dilutive equity capital three weeks ago. At a $208M market cap with ~$79M annual burn and no commercial timeline before 2028 at the earliest, the valuation is entirely sentiment-driven. A sentiment reversal — or just a quiet 11-day period with no positive news — brings the stock back toward $11-12.

What the data tells us:

• 📊 Vol/OI of 3,610x confirms this is entirely new positioning — no prior overhang
• 💰 MID fill confirms institutional execution — not a retail panic put
• 🕐 11-day expiration with near-zero time value = maximum urgency. This person wants to be positioned RIGHT NOW, not gradually
• 📈 KRRO's 85.1% annualized realized vol means 19% implied moves in 11 days are historically reasonable — the options market is pricing this correctly

If you're bearish on KRRO:

• ✅ The bear put spread approach ($15/$12) offers the best risk-adjusted entry: limited cost, aligned with gamma support, and captures the first leg of any reversal
• 📊 Watch the $15.00 gamma resistance level — a daily close above $15 with volume would invalidate the short-term bearish thesis
• ⏰ React quickly — with 11 DTE left on the institutional trade, the window for a profitable bearish position is closing fast

If you're bullish on KRRO:

• 🎯 The put activity is a warning sign that someone with presumably more information than the retail crowd is protecting against downside
• 📊 Analyst consensus at $34.80 is compelling, but the $22 median target vs. current $14.64 suggests even optimists don't expect a straight-line rally
• ✅ The $85M private placement from Venrock and other institutional investors represents true conviction money — these are not hot money tourists
• ⏰ Wait for Q1 earnings or the KRRO-121 IND filing update before committing new capital on the long side

If you're watching from the sidelines:

• 📅 Mark April 17, 2026 on your calendar — OPEX day will tell you whether this $2M put trade expires worthless (bullish for KRRO) or in-the-money (bearish confirmed)
• 🔬 The real make-or-break event is the KRRO-121 IND filing timeline. RNA editing as a modality is legitimate, and KRRO-121 targeting the ammonia pathway in UCD has genuine scientific rationale
• 📊 A stock that was at $55.89 less than a year ago, currently trading at $14.64, with analyst buy ratings and $34.80 consensus target, and $85M in fresh institutional capital — that's either a recovery story or a dead cat bounce. The options market is saying both simultaneously

Key dates to mark:

• 📅 April 17, 2026 — THIS TRADE EXPIRES; KRRO monthly OPEX. Options market expects price between $11.68 and $17.16
• 📅 Late April/Early May 2026 — Estimated Q1 2026 earnings release; first glimpse of cash position post-$85M raise
• 📅 Mid-2026 — Expected IND filing window for KRRO-121 in hyperammonemia
• 📅 Late 2026 — Possible first-in-human dosing for KRRO-121 if IND cleared
• 📅 Q4 2026/2027 — Phase 1 clinical data readout — the next true binary event

Final verdict: The $20 deep ITM put buying is more likely a profit protection mechanism than a pure crash bet — the math almost demands it. But regardless of intent, the signal is the same: someone with institutional resources and serious size is positioning for KRRO to be at or below $14.55 in 11 days. The stock has surged 79% YTD, has minimal gamma support below, is pricing in a 19% possible move in either direction, and carries all the scar tissue of a company that cratered 79% in a single day just five months ago. Respect the signal. Manage your risk accordingly.

The intrinsic value of caution is $0.09. That's what it cost this trader to buy insurance. Spend wisely. 🐻

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational purposes only and does not constitute financial advice. Deep in-the-money options carry significant capital risk including the potential for total loss of premium paid. Biotech stocks are subject to binary events that can move stock prices 50-80% in a single session. Always conduct your own research and consider consulting a licensed financial advisor before making trading decisions.

---

About Korro Bio: Korro Bio (formerly Keros Therapeutics) is a Cambridge, MA-based clinical-stage genetic medicines company developing RNA editing therapeutics for rare diseases, with lead candidate KRRO-121 targeting hyperammonemia in urea cycle disorders. Market cap approximately $208M on NASDAQ.